Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

ClinicalTrials.gov ID: NCT01445899

Public ClinicalTrials.gov record NCT01445899. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination With Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE STUDY)

Study identification

NCT ID
NCT01445899
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Quark Pharmaceuticals
Industry
Enrollment
258 participants

Conditions and interventions

Interventions

  • PF-04523655 (Stratum I) Drug
  • ranibizumab Drug
  • PF-04523655 (Stratum II) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2012
Primary completion
Oct 31, 2013
Completion
Oct 31, 2013
Last update posted
Feb 22, 2015

2012 – 2013

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
20
Facility City State ZIP Site status
Retina Consultants of Arizona Phoenix Arizona 85014
Retina Institute of California Arcadia California 91007
Retina-Vitreous Associates Beverly Hills California 90211
Retina Diagnostic Center Campbell California 95008
Retinal Consultants Medical Group, Inc. Sacramento California 95819
Orange County Reina Medical Group Santa Ana California 92705
MedEye Associates Miami Florida 33143
Center for Retina and Macular Disease Winter Haven Florida 33880
Southeast Retina Center Augusta Georgia 30909
Thomas A. Cuilla, MD, PC at Midwest Eye Institute Indianapolis Indiana 46290
Eyesight Ophthalmic Services, PA Portsmouth New Hampshire 03801
Retina Vitreous Center Toms River New Jersey 08755
Southeast Clinical Research Associates, LLC Charlotte North Carolina 28210
Black Hills Regioinal Eye Institute Rapid City South Dakota 57701
Tennessee Retina, PC Nashville Tennessee 37203
Retina Research Center Austin Texas 78705
Retinal Consultants of Houston Houston Texas 77030
Valley Retina Institute McAllen Texas 78503
Retinal Consultants of San Antonio San Antonio Texas 78204
Retinal Institute of Virginia Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01445899, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2015 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01445899 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →